SILu^™Lite APOA1 Apolipoprotein A-1 human

Apolipoprotein A-1(Apo-A1), is a major protein component of high density lipoprotein (HDL)in plasma¹. The protein promotes cholesterol efflux from tissues to the liver for excretion, and it is a cofactor for lecithin cholesterolacyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters². Apo-A1 was shown to assist in the improvement of predicting cardiovascular events³. The gene that encodes to Apolipoprotein A-1 is APOA1. This gene is closely linked with two other apolipoprotein genes on chromosome 11⁴. Defects in this gene are associated with HDL deficiencies, including Tangier disease⁵, and with systemic non-neuropathic amyloidosis⁶. The protein is made up of one major isoform (pI 5.6) and two minor isoforms (pI 5.53 and 5.46). Apo-A1 shows a high content of a-helix structure⁶. The amphipathic regions in the α-helix structure seem to be responsible for lipid binding capacity. In aqueous solution, Apo-A1 shows self-association with minor conformational change⁷. In addition, it has been shown that Apo-A1 is implicated in the anti-endotoxin function of HDL via interaction with lipopolysaccharide or endotoxin⁸.

Supplied as a lyophilized powder containing phosphate buffered saline.

General Description

SILuLite APOA1 is a recombinant human protein expressed in human 293 cells. It is a monomer of 286 amino acids (including N-terminal signal sequence and C-terminal polyhistidine and V5 tags), with a molecular weight of 32.1 kDa. SILuLite APOA1 is an analytical standard designed to be used as starting material for preparation of calibrators and controls in LC-MS applications.

Sequence

RHFWQQDEPPQSPWDRVKDLATVYVDVLKDSGRDYVSQFEGSALGKQLNLKLLDNWDSVTSTFSKLREQLGPVTQEFWDNLEKETEGLRQEMSKDLEEVKAKVQPYLDDFQKKWQEEMELYRQKVEPLRAELQEGARQKLHELQEKLSPLGEEMRDRARAHVDALRTHLAPYSDELRQRLAARLEALKENGGARLAEYHAKATEHLSTLSEKAKPALEDLRQGLLPVLESFKVSFLSALEEYTKKLNTQSDPSRGPFEGKPIPNPLLGLDSTRTGHHHHHHHHGGQ

The N-terminal signal peptide and C-terminal linker peptide, V5 and polyhistidine tags are italicized.

Other Characterization

• Sequence confirmed by intact mass analysis
• Identity verified by peptide mapping
• purity >98% (SDS-PAGE)
• Vial content was determined by the Bradford method using BSA as a calibrator. The correction factor of Bradford-to-AAA is 88.33%

Suggested Quantitative Analysis Parameters
(MRM settings provided for three suggested peptides)

SILu is a trademark of Sigma-Aldrich Co. LLC